Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A rare autoinflammatory syndrome defined as recurrence of pericardial inflammation of unknown origin following the first episode of acute pericarditis and a symptom-free interval of 4-6 weeks or longer. Recurrent attacks of chest pain may be the sole presentation or the chest pain may be accompanied by pericardial friction rub, electrocardiographic or echocardiographic changes, pericardial effusion and increased C-reactive protein. Cardiac tamponade is a rare, life-threatening complication.
Biomarker and diagnostic research for idiopathic recurrent pericarditis has been reported in the published literature.
Estimated prevalence: Unknown (Unknown prevalence).
1 clinical trial registered. Interventions under study include biologic therapy. Pipeline includes 1 PHASE3. Research is primarily industry-sponsored.
21 publications have been identified in PubMed for idiopathic recurrent pericarditis. Research spans Review / Meta-Analysis (24%), Case Report / Case Series (24%), and Clinical Trial Publication (19%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 5 | 24% |
Data assembled from 4 of 12 sources · Last updated Sep 19, 2026, 4:30 PM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Patient case studies |
5 |
24% |
Clinical study results | 4 | 19% |
Disease patterns and progression | 3 | 14% |
Testing and diagnosis research | 2 | 10% |
Other research | 1 | 5% |
Laboratory research | 1 | 5% |
Safiullina AА (2026). [PMID: 41705607](https://pubmed.ncbi.nlm.nih.gov/41705607/). *Terapevticheskii arkhiv*. [Review / Meta-Analysis]
Toker Dincer Z (2026). [PMID: 42033656](https://pubmed.ncbi.nlm.nih.gov/42033656/). *Intern Med J*. [Clinical Trial Publication]
Liu X (2026). [PMID: 42188104](https://pubmed.ncbi.nlm.nih.gov/42188104/). *J Cardiovasc Dev Dis*. [Case Report / Case Series]
Gunalp A (2026). [PMID: 42141100](https://pubmed.ncbi.nlm.nih.gov/42141100/). *Eur J Pediatr*. [Epidemiology / Natural History]
Feldman JM (2026). [PMID: 38709249](https://pubmed.ncbi.nlm.nih.gov/38709249/). *Cardiol Rev*. [Review / Meta-Analysis]
Collini V (2025). [PMID: 41210896](https://pubmed.ncbi.nlm.nih.gov/41210896/). *European heart journal. Case reports*. [Case Report / Case Series]
Wu MA (2025). [PMID: 41066128](https://pubmed.ncbi.nlm.nih.gov/41066128/). *JAMA Netw Open*. [Clinical Trial Publication]
Michaud M (2025). [PMID: 40164317](https://pubmed.ncbi.nlm.nih.gov/40164317/). *Int J Cardiol*. [Clinical Trial Publication]
Reddy SG (2025). [PMID: 40376326](https://pubmed.ncbi.nlm.nih.gov/40376326/). *Cureus*. [Case Report / Case Series]
Rafique S (2025). [PMID: 40636653](https://pubmed.ncbi.nlm.nih.gov/40636653/). *Cureus*. [Diagnostic / Biomarker]
AI-curated news mentioning idiopathic recurrent pericarditis
Updated Sep 14, 2026
Research indicates that goflikicept may modulate immune responses in patients with idiopathic recurrent pericarditis, as revealed by single-cell RNA profiling. This study could pave the way for new therapeutic strategies in managing this condition.
A recent study published in PubMed examines clinical outcomes in patients with multiyear recurrent pericarditis after stopping long-term interleukin-1 pathway inhibition. The findings provide valuable insights for chronic management strategies in this patient population.
Researchers have identified novel serum proteins that differentiate idiopathic recurrent aphthous stomatitis from Behcet's disease. This discovery could enhance diagnostic accuracy and improve patient management for these conditions.